Funding
← Back to your selection

NAVER D2SF

Activity from announced rounds

Activity in this selectionOct 9, 2026 · Asia · Jan 1, 2026

NAVER D2SF is NAVER’s startup investment organization, identified through official materials for ImpriMed and NdotLight.

Recorded funding activity

ImpriMed combines live-cell drug testing with clinical data. NdotLight generates simulation-ready 3D data, while F4GE structures factory information for industrial buyers. The organization retains its identity separately from NAVER Ventures and the parent.

Sources
Rounds participated in
6
Confirmed lead rounds
0
5 roles undisclosed
New companies
6
First participation on record · 0 follow-on
Funding in participating rounds
$20.6M
2 disclosed · full round size, not this investor’s share

By stage

Undisclosed3
Pre-seed1
Seed1
Series B1

By primary sector

Healthtech2
Robotics2
Defense tech1
Ecommerce1

By country

South Korea6

Rounds

6 in this selection
ImpriMed

A precision-oncology service that tests live cancer cells against drugs and uses clinical data to predict which treatments may work best for each patient.

$10MSeries A2 bridge
Participant
F4GE

Standardizes Korean factory data to connect manufacturers with global defense and industrial buyers

Role not disclosed
NdotLight

Generates simulation-ready 3D data for physical AI training

₩15BSeries B
Role not disclosed
SAZO

Cross-border shopping infrastructure connecting commerce platforms with payments, logistics and customs processes.

UndisclosedStrategic
Role not disclosed
Nuvilab

Develops AI-powered nutrition analytics solution for healthcare

UndisclosedUndisclosed
Role not disclosed